Question 1

What is MK-677?

Accepted Answer

MK-677 is a small molecule taken by mouth, and it belongs to a class called growth hormone secretagogues — compounds that push the pituitary gland into releasing more of the body's own growth hormone. A 1998 review calls them synthetic, non-natural peptidyl and nonpeptidyl molecules with a potent stimulatory effect on the pituitary, and places MK-677 among the nonpeptidyl ones. A 2018 review of the class describes ibutamoren mesylate as the one orally available small molecule in it. The published human trials run from 1996 to 2011, which is why there is a human record here to read at all. One compound carries several names: MK-677, MK-0677, ibutamoren, and more recently LUM-201.

Question 2

Is MK-677 a peptide?

Accepted Answer

Not in the chemical sense. Peptides are short chains of amino acids. The 1998 review that catalogues this class separates the peptide secretagogues, such as GHRP-1, GHRP-2 and hexarelin, from the nonpeptide ones, and names MK-677 — a spiroindoline derivative, built on a different chemical skeleton — among the second group. It reaches the same receptor by other means, and it is potent, long-acting and active when swallowed, which the injected peptides in the family are not. A 2026 scoping review in sports medicine still examined it alongside six compounds filed under the peptide heading, including BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu. So the search term and the chemistry disagree, and it is the chemistry the studies are about.

Question 3

Does MK-677 actually raise growth hormone?

Accepted Answer

That part is settled, and the hormone measurements are the best-replicated observations in the literature. In a 1996 randomised trial, 32 healthy participants aged 64 to 81 received either placebo or one of three daily amounts by mouth, and two weeks of MK-677 increased growth hormone in a dose-dependent way. At the highest amount, average IGF-1 — the hormone that carries most of growth hormone's effects — moved into the concentration range normally seen in young adults. A 1998 trial in 24 obese men ran eight weeks and found fat-free mass increased on a body composition scan, while total and visceral fat were unchanged. A two-year trial published in 2008 kept 65 healthy adults aged 60 to 81 on 25 mg daily: mean fat-free mass rose 1.1 kg in that group and fell 0.5 kg on placebo. Every outcome in that paragraph is a laboratory value or a measurement from an imaging machine.

Question 4

Did the lean mass turn into strength or function?

Accepted Answer

This is where the record thins out considerably. The two-year trial stated in its own limitations that its power — the duration and the number of participants — was insufficient to evaluate functional end points. The 2011 trial that tried hardest randomised 123 elderly hip fracture patients to 25 mg daily or placebo for 24 weeks. IGF-1 concentrations rose by 51 ng/ml against placebo, and gait speed registered a small difference favouring MK-677. There was no improvement in several other measurements of physical performance. A 1998 crossover study in eight calorie-restricted volunteers recorded daily nitrogen balance of 0.31 g on MK-677 against -1.48 g on placebo, which represents a protein-sparing observation collected from urine. Lean mass on a scan and a person who can climb a flight of stairs are different questions, and the second one is what most readers are actually asking.

Question 5

Why was one trial stopped early?

Accepted Answer

The 2011 hip fracture trial was terminated early because of a safety signal of congestive heart failure in a limited number of patients. Its authors concluded that MK-0677 has an unfavourable safety profile in that patient population. Those patients were old, frail and recently fractured, which is both the group most likely to produce such a signal and the group least like a healthy 25-year-old. That cuts both ways: it limits how far the finding travels, and it is also the only trial here that followed sick people long enough to see it. A 2026 scoping review carried the finding forward, listing congestive heart failure among the significant risks associated with MK-677. No other trial among the research behind this page reports the same event.

Question 6

What does MK-677 do to blood sugar?

Accepted Answer

Something, consistently, and quickly. In the 1996 trial in healthy older adults, fasting glucose rose from 5.4 to 6.8 mmol/L over four weeks on the highest daily amount. In the 1998 trial in obese men, fasting glucose and insulin held steady, but a glucose tolerance test — a measured sugar drink followed by timed blood draws — showed impaired glucose handling at both two and eight weeks. A 2018 review of the class gives the same reading for all of them: concern about rising blood glucose because insulin sensitivity falls. A 2026 review lists insulin resistance among the documented risks of these compounds. This is the most reproducible unwanted effect in the human record, and it turned up within weeks, in people who were metabolically healthy when they started.

Question 7

Does MK-677 increase height?

Accepted Answer

No study among the research behind this page measured adult height, and the work that comes closest was not designed to ask. In 18 prepubertal children with growth hormone deficiency, seven to eight days of oral ibutamoren raised growth hormone, IGF-1 and IGFBP-3, and the authors concluded only that it is worth testing for an effect on growth velocity. A 2022 report compared a single dose against the standard stimulation tests in 68 children and found a larger hormone response. A 2025 review notes preliminary data in children with partial deficiency. All of that is hormone response over days, in children whose growth plates are still open. In rats, six weeks of oral MK-677 did not increase body growth or IGF-1 at all, and the hormone response itself had been abolished by week six. A hormone level rising for a week is not the same as a child growing taller over a year, and in an adult the plates have already closed.

Question 8

Does MK-677 affect testosterone?

Accepted Answer

The only human record among the research behind this page that tracked sex hormones is a single case report, and it is confounded by its own design. A 25-year-old man took LGD-4033 and MK-677 together, daily, for five weeks. Free testosterone fell 85.7% and total testosterone 62.3%, with sex hormone-binding globulin down 79.6%, and all of those values returned to where they started after he stopped. LGD-4033 is a selective androgen receptor modulator, and suppressing the body's own testosterone is a known property of that class. Attributing the fall to MK-677 would be a guess, and that is not a question one case can settle. The seven-to-eight-day trial in children recorded no change in prolactin, cortisol, thyroid hormones, glucose or insulin — a different hormone panel, over days, in children.

Question 9

What side effects are documented in people?

Accepted Answer

Two kinds of record exist and they carry very different weight. In the 2001 bone trial, growth-hormone-mediated side effects were noted in the groups receiving MK-677, though few participants left the study because of them. The case reports are sharper and narrower. A 2025 report in BMJ Case Reports describes an otherwise healthy man in his early 30s who developed transaminitis — raised liver enzymes — after two months of MK-677, with liver tests returning to normal after he stopped; the same report lists swelling, a sharper appetite and muscle pain as the usual complaints and calls liver toxicity scarce in the published literature. The 2022 case of combined use recorded liver enzymes up 96% and 205%. A 2026 report describes a 54-year-old man using MK-677 and RAD-140 who presented with a ruptured spleen, and its authors call that link speculative. A case report is one person, and it cannot say how often anything happens.

Question 10

What did the bone trial find?

Accepted Answer

A 2001 trial randomised 292 women aged 64 to 85 with low bone density at the femoral neck into four daily groups for 12 months: MK-677 with alendronate, alendronate alone, MK-677 alone, or placebo. The combination raised bone density at the femoral neck, 4.2% against 2.5% for alendronate alone. The same enhancement was not seen at the lumbar spine, the total hip or the total body. The authors' own conclusion is the useful part: the femoral neck is an important site for fracture prevention, and the lack of gains elsewhere is a concern when weighed against the side effects of raising growth hormone. This is the largest controlled trial of MK-677 among the research behind this page, and its positive result covers one skeletal site out of four measured.

Question 11

How long does MK-677 stay in the body?

Accepted Answer

Reviews describe ibutamoren as potent, long-acting and orally active, which is why the trials administered it once daily. A measured human half-life is not among the research behind this page. What has been measured sits in two unusual places. In thoroughbred horses given it by mouth, ibutamoren itself remained detectable for up to 72 hours, and its major breakdown products for up to 96 hours. In people, a 2026 hair analysis found a single 10 mg exposure still registering at 1.3 pg/mg in the first centimetre of hair four weeks afterwards. The same analysis measured 224 pg/mg across a four-centimetre segment from a person who had consumed a 60-capsule vial over 90 days. Elimination from blood and detection in hair are different questions, and hair preserves a record of exposure for months after the compound itself has disappeared.

Question 12

Where does MK-677 stand in drug-tested sport?

Accepted Answer

Anti-doping laboratories have spent a decade learning to find it. That settles the question better than any argument about what counts as natural. A 2021 study mapped its breakdown products in horse liver preparations, and a 2022 study did the same in thoroughbred horses. Both papers give the same reason for the work: detecting the illegal use of ibutamoren in competitive sport. A 2026 paper on hair testing opens on hearings at the Court of Arbitration for Sport. There, anti-doping authorities have argued that hair results must be read with great care. A separate 2021 analysis notes that selective androgen receptor modulators have sat on the World Anti-Doping Agency prohibited list for more than a decade. The same analysis found MK-677 undeclared inside products sold as those modulators. For anyone who gets tested, the laboratories have already settled the practical question.

Question 13

Is MK-677 approved for anything?

Accepted Answer

It is not an approved medicine. A 2017 JAMA analysis called ibutamoren exactly that, an unapproved drug, when it turned up inside products sold online as something else. Development has carried on in one narrow place. Under the name LUM-201, ibutamoren was described in 2022 as being developed for growth hormone deficiency in children. A 2025 review reports early data in children with partial deficiency. Two registered studies sit in the public trial registry: an early-phase study of body composition and function in older adults, listed as completed, and a Phase 2 study in fatty liver disease, also listed as completed. Being studied and being approved are different states, and MK-677 has been in the first one since 1996.

Question 14

What have laboratories found inside products sold as MK-677?

Accepted Answer

Three surveys have opened such products and measured the contents. A 2017 JAMA analysis bought 44 products marketed online as selective androgen receptor modulators. Seventeen of them held a different unapproved compound, ibutamoren among them. In 26 of the 44, the measured amount differed substantially from the label. Four of the 44 held no active compound at all. A 2021 method paper applied the same approach to 60 products bought from international vendors, and found MK-677 present without appearing on the label. A five-year European survey, across 14 laboratories in 13 countries and 324 samples, reported ibutamoren as the most frequently identified of the 18 molecules it screened for. Most of those samples held active amounts and some held more than stated. These are measurements of contents, not of labels.

Question 15

What else is in the same class as MK-677?

Accepted Answer

A 2020 review of this class in men with low testosterone lists the family together: sermorelin, GHRP-2, GHRP-6, ibutamoren and ipamorelin. The 1998 review adds hexarelin and GHRP-1 and describes them all as acting through one receptor, which is what makes them a class at all. The practical split inside it is route and duration — the peptides are injected and short-acting, MK-677 is swallowed and long-acting. Similar is doing a lot of work in that sentence, though. The same 2020 review says a paucity of data on clinical effects limits what can be said about any of them, so comparing two members means comparing two thin records rather than two outcomes.

Question 16

How is MK-677 thought to work?

Accepted Answer

It acts on the growth hormone secretagogue receptor, the same one the stomach hormone ghrelin uses, and that receptor sits both in the pituitary and in the hypothalamus above it. The 1998 review notes that it has been cloned and bears no structural resemblance to the receptor for growth hormone-releasing hormone, which is why the two kinds of compound are not interchangeable. Because MK-677 works through the pituitary instead of supplying growth hormone from outside, release stays pulsatile — in bursts — and stays under the body's own feedback control, which a 2018 review gives as the argument for the class. The animal work marks two limits. In rats, six weeks of dosing abolished the hormone response while somatostatin, the brain's brake on growth hormone, rose in the hypothalamus. In isolated rat heart muscle, MK-677 reduced contractility.

MK-677